HealthTech Marketing Lessons from Flow Neuroscience

Depression is one of the most expensive “invisible” problems in healthcare—expensive for patients, for employers, and for systems like the NHS that are already under pressure. That’s why Flow Neuroscience’s traction stands out: 50,000+ people have used Flow, and it’s now in use across 600+ clinicians and hospitals in Europe, with reported outcomes like ~77% seeing meaningful improvement within three weeks and 50%+ free from depression after ten weeks (per Flow’s clinical data shared by founder Daniel Månsson).

Those numbers aren’t only a product story. They’re a marketing story—because in HealthTech, credibility is the channel. If you’re building anything that touches patient outcomes (apps, devices, diagnostics, digital therapeutics), the old playbook of flashy growth hacks falls apart fast. Evidence, regulation, clinician trust, and patient clarity do the heavy lifting.

This post sits within our Healthcare & NHS Reform series for a reason: the NHS capacity conversation often misses a practical truth. Home-based, clinically evidenced treatment pathways can reduce demand on overstretched services—if (and only if) they’re adopted. And adoption is largely a marketing problem dressed up as “innovation.”

Flow’s biggest advantage: evidence-led positioning (not hype)

The fastest route to HealthTech growth in the UK and Europe is simple to state and hard to execute: earn trust with proof, then scale distribution through clinical pathways. Flow’s approach, as described by Daniel Månsson in TechRound’s interview, reinforces that.

Flow combines:

• A medically approved brain stimulation headset using tDCS (transcranial direct-current stimulation)
• A therapy app delivering evidence-based behavioural support (sleep, nutrition, exercise, meditation)

The marketing lesson is the packaging: Flow doesn’t present itself as “wellbeing.” It presents itself as treatment for depression, with a medical-grade device and clinical outcomes attached.

What UK startups can copy: the “regulation-first” narrative

Most companies avoid regulation in their messaging because they think it slows sales. In HealthTech, that’s backwards.

Here’s the better stance:

If you’re asking clinicians, commissioners, or employers to take you seriously, your regulatory status isn’t a footnote—it’s your headline.

Flow’s positioning benefits from being described as medically certified for home use in the UK and EU. That phrase does three jobs at once:

1. Reduces perceived risk for patients
2. Signals legitimacy to clinicians and hospital buyers
3. Creates a moat against “wellness” competitors

If your HealthTech product isn’t regulated (yet), you can still market like a grown-up:

• Be specific about your intended use and limitations
• Publish your evaluation plan (what you’ll measure, when, and why)
• Use precise language: support, monitor, screen vs treat

Build a brand around the problem, not the technology

Flow’s origin story is also a branding lesson. Månsson’s background is in clinical psychology, and his co-founder Erik Rehn is an engineer and computational neuroscientist. Their insight: depression isn’t only a “chemical imbalance” framing—it’s also about brain activity and connectivity.

The temptation for founders is to lead with the cleverness: tDCS, neuromodulation, dorsolateral prefrontal cortex. Flow does include those specifics, but the customer-facing arc is clearer:

• Depression treatment is hard to access
• Side effects and waiting lists create drop-offs
• Home-based, evidence-backed options can close the gap

NHS reform context: access is the brand promise

In the UK, mental health demand and waiting lists continue to define real-world patient experience. For startups, this creates a tough reality and a huge opportunity:

• Patients want faster access
• GPs and IAPT-style services need options that are safe and referable
• ICSs and trusts need interventions that reduce downstream load

A strong HealthTech brand doesn’t promise miracles. It promises access + safety + measurable outcomes.

Flow’s story is essentially: “Take validated science out of the lab and into the home, responsibly.” That’s a compelling reform-aligned message because it maps to system goals: capacity, cost control, and earlier intervention.

Credibility is the hardest part—and it’s also your best moat

Månsson calls the biggest challenge “credibility,” especially with anything involving brain stimulation. That’s the most honest line in the interview, and it’s the one most founders should print out and tape above their desk.

HealthTech marketing fails when companies treat skepticism like an obstacle to overcome with better copywriting. Skepticism is a feature of the market. You earn your way through it.

The credibility stack: what to build (and how to market it)

If you want clinicians, NHS partners, or serious employers to adopt your product, build a credibility stack and make it visible:

1. Clinical evidence: trials where appropriate, plus real-world outcomes (clearly labelled)
2. Regulatory progress: CE/UKCA pathways, FDA signals if relevant (Flow mentions FDA Breakthrough Device designation)
3. Clinical workflow fit: training, onboarding, support, safety monitoring
4. Manufacturing and QA maturity: boring, vital, and often missing from startup storytelling
5. Clear patient instructions: reduce misuse risk, reduce support burden

And here’s the marketing takeaway:

Your proof needs to be as easy to find as your pricing.

If your evidence is buried in a PDF no one can access, you’re choosing slower growth.

Thought leadership that actually drives leads: interviews, clinicians, and specifics

The TechRound interview itself is a growth channel. Not because “press is nice,” but because it builds three assets:

• A founder narrative (why this exists)
• A credibility narrative (how you validate it)
• A distribution narrative (where it’s used and by whom)

Most startups do thought leadership wrong by being generic. Flow’s story isn’t generic. It includes numbers and mechanisms.

A practical playbook for UK HealthTech founders

If you’re trying to generate leads (clinical, employer, or direct-to-consumer), here’s what works in 2026:

• Lead with measurable outcomes (even if early): e.g., time-to-improvement, adherence, dropout rates
• Name the user and the buyer separately: patient vs clinician vs commissioner vs employer
• Publish a “Who it’s for / Who it’s not for” section: it reduces friction and increases trust
• Use clinician voices as validators: advisory boards, pilots, and service evaluations
• Turn one interview into ten assets:
  • 3 short posts on outcomes
  • 2 posts on regulation and safety
  • 2 posts on NHS pathway fit
  • 1 founder story clip
  • 1 FAQ piece addressing risk concerns
  • 1 partner-focused one-pager

I’ve found that the highest-performing HealthTech content is the least “creative.” It’s the content that answers procurement and clinical questions clearly.

What Flow’s model suggests for NHS capacity and modern care pathways

Home-use interventions aren’t automatically “NHS reform.” They only help if they:

• Are safe enough to deploy widely
• Reduce clinician time per patient (or improve outcomes for the same time)
• Fit referral pathways and governance
• Offer measurable follow-up and escalation

Flow’s combined device + app approach is notable because it blends neuromodulation with behavioural support. That matters: systems don’t only need symptom reduction—they need relapse prevention and self-management support.

People also ask: “Is home brain stimulation realistic at scale?”

Yes, if the model is designed around safe use and compliance. The interview highlights “scaling responsibly” as a core challenge: manufacturing safely, providing clinical support, and ensuring correct use.

If you’re marketing a home-use medical product, you should assume your audience is thinking:

• What happens if someone uses it incorrectly?
• How do you monitor adverse events?
• Can a clinician supervise without adding workload?

Answer those questions upfront and your conversion rates will improve—because you’re reducing perceived risk.

People also ask: “How do we get adopted by the NHS?”

Adoption comes from pathway fit + proof + procurement readiness. The interview suggests Flow is working toward integration with systems like the NHS.

For startups, that means:

• Map where you sit: GP, community services, secondary care, employer OH, self-referral
• Show economic logic: cost per recovered patient, reduction in appointments, improved return to work
• Prepare for long cycles: pilots, evaluations, governance, IG, clinical safety

If your marketing doesn’t reflect those realities, you’ll keep attracting the wrong leads.

The stance I’d take if I were marketing a HealthTech device in the UK

Here’s the blunt version: stop trying to sound exciting and start trying to sound safe, specific, and useful.

Flow’s story shows that you can still build a strong brand with that approach. You just anchor it in:

• A real unmet need (access to depression treatment)
• A defendable mechanism (tDCS + behavioural therapy)
• Clear validation signals (clinical outcomes, clinician adoption, regulatory milestones)

That’s not “slow marketing.” It’s marketing that compounds.

If you’re building in the UK HealthTech ecosystem and you want leads—NHS conversations, clinical partners, employer deals—your next step is to audit your messaging like a commissioner would. Does it read like a safe pathway option, or like an app store listing?

The NHS reform agenda isn’t waiting for more ideas. It’s waiting for deployable, evidenced solutions that can scale without breaking governance. Which side of that line is your startup on?